AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04363944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mRehab
Description: mRehab (mobile Rehab) was created to better support in-home upper limb rehabilitation programs. It incorporates a task-oriented approach and immediate performance-based feedback. mRehab consists of 3D-printed household items (a mug, bowl, key, and doorknob) integrated with a smartphone and an app. The app guides participants through practice of activities of daily living (ADL), for example, sipping from a mug. It can also consistently measure time to complete an activity and quality of movement (smoothness/accuracy) during the performance of ADLs. In each session of exercise participants receive feedback on the number of repetitions they complete for each activity, the average time to complete the activity and the average smoothness to perform the activity. Participants were trained in use of mRehab in lab visits and then took mRehab home to use the system. mRehab recorded longitudinal data.
Study NCT03256136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study NCT03256136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: will allow the body's immune system to work against tumor cells
Study NCT03256136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Chemo therapy
Study NCT00798876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E supplement
Description: Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
Study NCT00798876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Western Diet
Description: Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
Study NCT00798876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet
Description: Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
Study NCT00798876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Examination
Description: Subjects will have a routine medical exam.
Study NCT00798876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medical Examination
Description: Subjects will have a routine medical exam.
Study NCT04663698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH
Study NCT00798876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Interview
Description: Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
Study NCT03379168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sterile saline injection will act as a placebo group.
Study NCT04663698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MESH-Resistor 5
Description: Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow
Study NCT03256136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: will allow the body's immune system to work against tumor cells
Study NCT04110444 — intervention group
Intervention type: DRUG
Intervention: Sildenafil
Description: oral sildenafil t.d.s for high-risk pregnancies
Study NCT01171742 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intermittent hepatic inflow occlusion (IHIO)
Description: Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
Study NCT01171742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent hepatic inflow occlusion (IHIO)
Description: Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
Study NCT00798876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Interview
Description: Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
Study NCT00798876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: 40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
Study NCT00798876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood Draw
Description: 40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
Study NCT00798876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Subjects will undergo a radical prostatectomy as part of their standard of care.
Study NCT00798876 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Radical Prostatectomy
Description: Subjects will undergo a radical prostatectomy as part of their standard of care.
Study NCT04663698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MESH-Resistor 10
Description: Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (10hPa/L) to create laminar airflow
Study NCT04663698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perforated Resistor 7
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 7mm) to create a turbulent airflow
Study NCT00866190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
Study NCT03527186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM® 100 mg
Description: 100 mg of risperidone ISM® administered every 4 weeks
Study NCT01755338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 15mg/kg
Study NCT01755338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03587467 — intervention group
Intervention type: OTHER
Intervention: collect fecal specimens
Description: collect fresh fecal specimens of participants
Study NCT00675688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene/Conjugate Estrogens (CE)
Study NCT00675688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Study NCT00675688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02943668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Given PO
Study NCT02943668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02773472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: The acupoints that will be stimulated are: daheng, tianshu, zhongwan, xiawan, qihai, guanuian, hegu, guchi, zusanli, sanyinjiao, gongsun. An alternating fast-slow frequency of 20Hz/6Hz will be used with an interval of 250msec. The intensity (mA) will be adjusted to a level tolerated by each individual patient.
Study NCT02773472 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: morphine
Description: Patient will not receive electroacupuncture. Patient will use morphine for analgesia.
Study NCT00425945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pine Bark Extract (Flavangenol®)
Description: Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.~Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks.
Study NCT00425945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pine Bark Extract (Flavangenol®)
Description: Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.~Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks.
Study NCT04389268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Event-Related Potentials
Description: Auditory P300-evoked brain potential: an eventrelated potential of cognitive neurophysiological significance. It represents the brain response to certain sensory/cognitive stimuli by paying attention to the different stimulus among the stereotypical ones (the auditory oddball paradigm). It measures mainly the decision-making process (Polich and Kok, 1995).
Study NCT00878306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram
Description: 62.5 mg daily x3 days, then 250 mg daily x3 days
Study NCT00878306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram + Efavirenz
Description: Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
Study NCT00878306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram + Atazanavir
Description: Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
Study NCT00878306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram + Ritonavir
Description: Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
Study NCT02195947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
Study NCT01099761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031 0.5 mg/kg q4wk
Description: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
Study NCT01099761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031 1.0 mg/kg q2wk
Description: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
Study NCT01099761 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
Study NCT02803814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior mesenteric artery approach for pancreatoduodenectomy
Description: Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the superior mesenteric artery approach
Study NCT02803814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic approach for pancreatoduodenectomy
Description: Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the classical approach
Study NCT02090673 — intervention group
Intervention type: DRUG
Intervention: Exenatide
Study NCT04533516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy technics
Description: Manual therapy technics
Study NCT04533516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: Inspiratory Muscle Training
Study NCT04533516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory Muscle Training
Study NCT02550119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Given PO
Study NCT02550119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT02550119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT02550119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolasetron Mesylate
Description: Given PO or IV
Study NCT04663698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perforated Resistor 11
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 11mm) to create a turbulent airflow
Study NCT04291638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Caregiver Training
Description: The remote caregiver training is a 5-hour videoconferencing-based training program that focuses on teaching cognitive behavioral therapy skills to the caregivers of children with selective mutism in a group format across 3 sessions.
Study NCT04291638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Intensive Group Behavioral Treatment (IGBT)
Description: The remote IGBT is a 5-day videoconferencing-based treatment program that delivers cognitive behavioral therapy to children and their caregivers in a group format across 2-3 hours per day.
Study NCT02550119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dolasetron Mesylate
Description: Given PO or IV
Study NCT02550119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT04192318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridging the Gap
Description: Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.
Study NCT03000595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN007 Cream
Description: A cream containing 5% East Indian sandalwood oil (EISO).
Study NCT03000595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The vehicle cream
Study NCT02531841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)
Description: Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):~* Rituximab 375 mg/m²/d i.v. (d0)~* Dexamethasone 40 mg/d i.v. (d1-3)~* Etoposide 100 mg/m²/d i.v. (d1-3)~* Ifosfamide 1500 mg/m²/d i.v. (d1-3)~* Carboplatin 300 mg/m² i.v. (d1)
Study NCT02531841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
Description: 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation~High-dose chemotherapy (HDT-ASCT):~* Carmustine\* 400 mg/m² i.v. (d-6)~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)~  \* if carmustine is not available at the investigation site, busulfan can be administered instead:~* Busulfan 3,2 mg/kg/d (d-8-(-7))~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)
Study NCT01526954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TissuGlu Surgical Adhesive
Description: TissuGlu Surgical Adhesive to be used prior to closure of the large tissue flap in abdominoplasty cases.
Study NCT03822520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 400mg capsule
Study NCT03822520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400mg tablet
Study NCT03822520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Pure water 150ml
Study NCT02378922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene-Modified HIV-Protected Hematopoietic Stem Cells
Description: Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV
Study NCT02378922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02378922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transplant Conditioning
Description: Undergo high-dose chemotherapy or chemoradiotherapy
Study NCT03865199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Intervention
Description: Participants in the intervention group will first view a digital story on a tablet with headphones that will combine a fictional patient's abortion story with basic medical and social facts regarding abortion. After viewing the narrative, participants will be asked to write a narrative either on a tablet provided or on paper with the prompt: Patients have different thoughts and feelings about their experiences when they have this procedure. Tell a story (about yourself or someone else, real or imaginary) that might help another patient feel supported.
Study NCT04192318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communities that Care (CTC)
Description: In CTC programs stakeholders elect evidence-based prevention strategies that are most appropriate for their community. These evidence-based strategies target their community's specific needs, such as reducing risk factors while supporting and increasing protective factors.
Study NCT04192318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treat and release
Study NCT04192318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treat and release
Study NCT01171313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP21279 and carbidopa (experimental)
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa
Study NCT00124735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bolus maintenance
Description: Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation
Study NCT00124735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium continuous infusion maintenance
Description: Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation
Study NCT03572803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group of Dry Needling
Description: Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
Study NCT03572803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group of Electrolysis
Description: Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
Study NCT03572803 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
Study NCT03576521 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CT + Ocoxin-Viusid
Description: The included patients received the Ocoxin-Viusid nutritional supplement at a rate of 75 ml daily (25 ml in 3 doses every 8 hours) administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center.
Study NCT03576521 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: CT + Placebo
Description: The included patients received the OV placebo in oral solution at a rate of 75 ml daily (25 ml in 3 doses every 8 hours), administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center.
Study NCT00772044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provent Professional Sleep Apnea Therapy Device
Description: Application of active device (Provent)
Study NCT00772044 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham device will be applied
Study NCT01323686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging guided optimal LV lead placement
Description: LV lead placement guided by cardiac imaging using echocardiography, single-photon emission computed tomography, and CT to target a cardiac vein at the site of latest mechanical activation without scar tissue.~Visualization of cardiac venous anatomy is performed using cardiac CT if not contraindicated by depressed renal function (estimated glomerular filtration rate \<30 ml/min) or allergy to contrast media. In that case, a coronary venogram is used.